Posted on 23 July 2014.
Investment firms backed by Enterprise Ireland invested €5m more last year than in 2012, according to the semi-State agency.
Firms using its Seed and Venture Capital Programmes invested €59m in 94 companies during 2013, it said, compared to a €54m investment in 84 companies during 2012.
To date half of the investments made via the programme were in the software sector, with more than a third going into life science firms.
The programme currently manages almost €700m in capital, according to Enterprise Ireland, with around 2,100 people employed by the firms that have gained investment through it to date.
Minister for Enterprise Richard Bruton said venture capital funds provide “critical funding, mentoring and access to networks” for emerging companies, with the latest figures showing that the State has been successful in encouraging more VC activity here in recent years.
Posted in Innovation, News, R&D Investment, R&D News
Posted on 02 May 2014.
BioMarin Manufacturing Ireland, a subsidiary of BioMarin Pharmaceutical Inc., is to add the positions at its Dublin Global Commercial Operations Hub.
The expansion follows the announcement earlier this week that the European Commission had approved VIMIZIM, an enzyme replacement drug made by BioMarin.
The jobs will be in accounting, finance, customer service and marketing.
The Dublin operation has responsibility for international supply chain, logistics and high-level commercial decision making, including price, distribution and third party contracts for the launch of VIMIZIM.
BioMarin also has a biopharma manufacturing facility in Shanbally in Cork, which is expected to grow to 140 employees by 2015.
The investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Minister for Jobs, Enterprise and Innovation Richard Bruton said the announcement was a further boost for the sector and for the city.
BioMarin Vice-President James Lennertz described Ireland as an ideal business environment and said Dublin was an essential part of the company’s strategy.
Posted in Appointments, Healthcare, Medical Research, R&D News